This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Etoposide
  • /
  • A Randomized, Open-label, Safety and Efficacy Stud...
Clinical trial

A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Read time: 2 mins
Last updated:1st Jul 2016
Identifier: NCT02703272
The purpose of this study is to confirm that the pharmacokinetics of ibrutinib in pediatric participants is consistent with that in adults (part 1) and to assess efficacy (event-free survival [EFS]) of ibrutinib in combination with rituximab, ifosfamide, carboplatin, and etoposide (RICE) or rituximab, vincristine, ifosfamide, carboplatin, and idarubicin (RVICI) background therapy compared to RICE or RVICI background therapy alone (part 2).
Category Value
Date last updated at source 2017-06-01
Study type(s) Interventional
Expected enrolment 84
Study start date 2016-07-01
Estimated primary completion date 2021-06-29

View full details